ClinicalTrials.gg
Status unknownNCT02633475Updated Feb 15, 2017

Interleukin-10 Promoter-1082A/G Polymorphism and Idiopathic Recurrent Miscarriage Risk

An observational study in Abortion, Spontaneous, sponsored by Fourth Affiliated Hospital of Guangxi Medical University. Status unknown at 2 sites in China. Open to female participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-15.

Sponsored by Fourth Affiliated Hospital of Guangxi Medical University · Observational

How we know

The sponsor has not verified this record recently (last verified Feb 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
200
Ages
20 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Abortion, Spontaneous with a site in China — 4 open to participants now, 4 under way, none of them phase 3. Abortion, Spontaneous · China.

Planned enrollment
6th of 12
200 · median 200
Started
2015
the only one that year
Observational
12 of 15
2 open now
Registered
1st of 15
by date
Lead sponsor
1 of 15
Fourth Affiliated Hospital of Guangxi Medical University

Among the 15 studies in Abortion, Spontaneous with a site in China, this one is the 6th largest by planned enrollment of the 12 observational ones that give a count, is the only one that started in 2015, is one of 12 observational ones, and was the 1st registered.

Abortion, Spontaneous

221 studies on the registry are indexed under Abortion, Spontaneous; 44 are open to participants now.

Browse Abortion, Spontaneous studies →

Open to participants now

4 of the 15 studies in Abortion, Spontaneous with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 36 Abortion, Spontaneous studies recruiting now, 11 (31%) set no upper age limit and 25 (69%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 20 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Abortion, Spontaneous with a site in China, or all of them as a file.
02

Study summary

This study aimed to assess the correlation between the interleukin-10 (IL-10)-1082A/G polymorphism and idiopathic recurrent miscarriage (IRM) of Chinese Han. A total of 100 women with IRM and 100 control women with a successful pregnancy will be included in this study. Then genotyping will be performed.

Read the detailed description

As a common occurrence in early pregnancy, IRM has been associated with multiple causes, among which the disorders of immune homeostasis between the fetus and the maternal immune system, maintained by cytokines from the complex regulatory network, are considered one of the potential etiological factors underlying IRM.

The IL-10 polymorphism -1082A/G (rs1800896), which is located in the promoter region of the IL-10 gene, was reported to be implicated in the abnormal expression of IL-10 in IRM by some studies.

However, no such reports about the association between IL-10 polymorphism -1082A/G and IRM risk in Chinese Han.

03

Conditions studied

  • Abortion, Spontaneous

Browse trials for

Keywords

  • interleukin-10
  • Polymorphism, Single Nucleotide
04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Female patients who referred to the Fourth Affiliated Hospital of Guangxi Medical University or Liuzhou Maternity and Child Healthcare Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. women with more than three consecutive unexplained pregnancy losses before the 20th week;
  2. Chinese Han Population;
  3. Patients who signed .

Exclusion criteria

Exclusion Criteria:

  1. Patients who had other high-risk factors which might relate with recurrent miscarriage, including: (1) Parental karyotype abnormalities: significant rearrangements (e.g. balanced translocations and mosaics) were considered abnormal. If either the patient (or her partner) had an abnormal karyotype, it was considered a parental karyotypic abnormality; (2) Genital tract abnormalities: Any congenital anatomical deformation of the genital tract was considered abnormal; intrauterine adhesions, endometriosis and hydrosalpinx were also considered abnormal; (3) alloimmune disorder; (4) Endocrine abnormalities: prolactin (PRL) level >25 ng/ml, testosterone level >2.6 nmol/L, thyroid-stimulating hormone level \<0.30 mU/L or >4.5 mU/L, free thyroxine (FT4) level \<8.36 nmol/L or >29.6 nmol/L and free triiodothyronine (FT3) level \<1.84 nmol/L or >7.39 nmol/L. Glucose level > 126mg/dl; (5) disorders: Any positive results of Anti-cardiolipin antibodies (ACA-IgG/IgM/IgA), anti-nuclear antibodies (ANA-IgG), anti-endometrium antibodies (AEA-IgM), anti-ovary antibodies (AOA-IgM), anti-sperm antibodies (ASA-IgM), antithyroidin(TG-Ab), anti-thyroid peroxidase antibody(TPO-Ab) and/or anti-chorionic gonadotropin hormone antibody; (6) Hypercoagulation state: D-dimer levels >260 ng/ml, fibrin degradation products (FDP) levels >5 mg/L or anti-beta 2-glycoprotein I (anti-beta 2-GP1) levels >15 U/ml; (7) Negative RH blood groups; (8) Abnormal semen routine results of patients husband.
  2. Patients with serious diseases;
  3. Patients with administration of pills;
  4. Patients participated in other randomized clinical research;
  5. Patients could not be followed-up of a long time or had poor compliance;
  6. Patients with other factors that would affect the study result.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • CONTROL: women no miscarriage

    Group of patients who referred to the Fourth Affiliated Hospital of Guangxi Medical University or Liuzhou Maternity and Child Healthcare Hospital, who have more than one successful pregnancy without miscarriage. Then the blood sample will be collected and the IL-10 Polymorphism will be analyzed.

    Genetic: IL-10 polymorphism

  • CASE: patients with IRM

    Group of patients who referred to the Fourth Affiliated Hospital of Guangxi Medical University or Liuzhou Maternity and Child Healthcare Hospital, who have more than three consecutive miscarriages without clear cause (Idiopathic Recurrent Miscarriage, IRM). Then the blood sample will be collected and the IL-10 Polymorphism will be analyzed.

    Genetic: IL-10 polymorphism

Interventions

  • GeneticIL-10 polymorphism

    The IL-10 genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.

06

What researchers measure

Primary outcomes

  1. genetic polymorphisms associated with idiopathic recurrent miscarriage

    Identification of genetic polymorphisms that are associated with idiopathic recurrent miscarriage

    Time frame: within one year (plus or minus 1 month) after surgery

Secondary outcomes

  1. Indexes in the routine blood test and blood coagulation test

    To explore the differential indexes in the routine blood test and blood coagulation test between patients with idiopathic recurrent miscarriage and healthy women, such as: WBC, NEU, LYM, RBC, HB, RDW, MCV, PLT, MPV, PDW, PCT, Fib, D-dimer.

    Time frame: During pregnancy and three months after miscarriage

07

Study locations

2 of 2 sites recruiting
  • Liuzhou Maternal and Child Health Care Hospital
    Liuzhou, Guangxi 545000, China
    Recruiting
    • Xiaolan Lv · Contact
  • the Fourth Affiliated Hospital of Guangxi Medical University
    Liuzhou, Guangxi 545000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2015, a primary completion of Dec 2017 and a completion of Dec 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2015
First posted
Dec 17, 2015
Start
Aug 2015
Primary completionEst.
Dec 2017
CompletionEst.
Dec 2017
Last update
Feb 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02633475
Lead sponsor
Fourth Affiliated Hospital of Guangxi Medical University
Collaborators
Liuzhou Maternity and Child Healthcare Hospital
Responsible party
Sponsor
First posted
Dec 17, 2015
Start date
Aug 2015
Primary completion
Dec 2017 (estimated)
Completion
Dec 2017 (estimated)
Last update
Feb 15, 2017

Study contacts

Zheng Peng
Contact
labstar@qq.com
+86 18589966550
Xiaolan Lv
Contact
labsun@qq.com
+86 15577727711
Xiangcheng Wei
principal investigator · Guangxi Medical University Institutional Review Board

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion